Principal Financial Group
PSTX

Principal Financial Group’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Principal Financial Group’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,006
Closed -$35.1K – 2431
2024
Q2 		$35.1K Buy
+12,006
New +$32.8K ﹤0.01% 2312
2023
Q4 		– Sell
-10,000
Closed -$23.8K – 2465
2023
Q3 		$23.8K Buy
+10,000
New +$21K ﹤0.01% 2402

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Principal Financial Group's PSTX Position: Q3 2024 in Review

Principal Financial Group sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q3 2024, closing a stake of 12,006 shares — an estimated $35.1K sold.

Principal Financial Group first reported a position in PSTX in Q3 2023 and held it in 2 quarters. The position peaked at $35.1K in Q2 2024. 96 funds tracked by Wall St. Rank hold PSTX as of Q3 2024.

  • Principal Financial Group reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 12,006 Poseida Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $35.1K.
  • Principal Financial Group first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
  • Principal Financial Group's Poseida Therapeutics, Inc. Common Stock position peaked at $35.1K in Q2 2024.
  • 96 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.